Low LINC01272 predicts poor prognosis of non‑small cell lung cancer and its biological function in tumor cells by inhibiting miR‑1303

Abstract

Non-small cell lung cancer (NSCLC) is a malignant tumor associated with poor prognosis. The clinical value of long non-coding RNAs (lncRNAs) in the pathomechanism of various types of human malignancy has attracted increasing attention. The present study aimed to investigate the expression of LINC01272 in NSCLC and to determine its prognostic value and biological role. Tumor and adjacent non-tumor tissues from 108 patients with NSCLC and NSCLC cell lines were used in this study. The expression levels of LINC01272 and microRNA (miR)-1303 in tissues of patients and NSCLC cell lines were evaluated by reverse transcription quantitative PCR. The relationship between LINC01272 and the overall survival of patients with NSCLC was analyzed by Kaplan-Meier survival curve and log-rank test. Cox regression analysis confirmed the prognostic value of LINC01272 in patients with NSCLC. Cell Counting Kit-8 assay was used to evaluate the proliferation of NSCLC cells. The migration and invasion of NSCLC cells were determined using Transwell assays. The interaction between LINC01272 and miR-1303 in NSCLC was confirmed by dual-luciferase reporter assay. LINC01272 downregulation in NSCLC tissues was associated with worse overall survival in patients based on bioinformatics analysis. Furthermore, LINC01272 expression, which was decreased in NSCLC tumor tissues and NSCLC cells, was considered as an independent prognostic biomarker in NSCLC. In addition, LINC01272 overexpression inhibited NSCLC cell proliferation, migration and invasion. miR-1303 expression, which was increased in tumor tissues, was sponged by LINC01272 and negatively correlated with LINC01272 expression. miR-1303 expression reversed the inhibitory effects of LINC01272 on NSCLC cell function. In summary, the findings from this study suggested that LINC01272 expression, which was decreased in NSCLC tumor tissues and NSCLC cells, may be used as an independent prognostic biomarker for patients with NSCLC and that its overexpression may suppress NSCLC cell proliferation, migration and invasion by inhibiting miR-1303.

LncRNA PELATON, a Ferroptosis Suppressor and Prognositic Signature for GBM

“…PELATON is a long intergenic nonprotein coding RNA1272 (also known as LINC01272 ). Few studies have indicated that it promotes cancer cell migration and invasion, such as gastric cancer ( 51 , 52 ), colorectal cancer ( 53 ), and non-small-cell lung cancer ( 54 ), but there is no report in GBM. PELATON showed significantly higher expression in GBM tissues and primary GBM cells, which were named PG-2, PG-3, PA-2, and PA-3 ( 42 ), and was mainly located in the plasma membrane of GBM cells ( Supplementary Figure 5A and Figures 5A–C ).…”

Computational Recognition of LncRNA Signatures in Tumor-associated Neutrophils could have Implications for Immunotherapy and Prognostic Outcome of Non-small Cell Lung Cancer

“…A reduction in LINC01272 expression in tissues and cells of NSCLC patients may serve as an independent prognostic marker. LINC01272 overexpression may inhibit NSCLC cells proliferation, migration, and invasion by inhibiting MI-1303 [45]. LINC00261 downregulation in gastric cancer is associated with poor prognosis.…”

Inhibiting KCNMA1-AS1 promotes osteogenic differentiation of HBMSCs via miR-1303/cochlin axis

“…And qRT-PCR indicated that only the change in miR-1303 was statistically significant. Though it has been reported that miR-1303 can mediate cellular proliferation in several cancers [ 26 – 31 ], miR-1303 has not been investigated in osteoporosis.…”